Cyberonics, Inc.  

(Public, NASDAQ:CYBX)   Watch this stock  
Find more results for CYBX
71.98
+0.79 (1.11%)
Real-time:   3:47PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 70.85 - 72.24
52 week 48.19 - 76.48
Open 71.25
Vol / Avg. 353,976.00/666,077.00
Mkt cap 1.87B
P/E 29.38
Div/yield     -
EPS 2.45
Shares 26.03M
Beta 0.71
Inst. own 105%
Jun 2, 2015
Q4 2015 Cyberonics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 11, 2015
Cyberonics Inc at Barclays Healthcare Conference - 1:05PM EDT - Add to calendar
Feb 26, 2015
Q3 2015 Cyberonics Inc Earnings Release
Feb 26, 2015
Q3 2015 Cyberonics Inc Earnings Results and Cyberonics Inc and Sorin SpA M&A Conference Call - Webcast
Jan 14, 2015
Cyberonics Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Jan '15) 2014
Net profit margin 22.95% 19.46%
Operating margin 32.84% 28.37%
EBITD margin - 33.00%
Return on average assets 22.18% 19.67%
Return on average equity 24.53% 22.47%
Employees 639 -
CDP Score - -

Address

100 Cyberonics Blvd
HOUSTON, TX 77058-2069
United States - Map
+1-281-2287200 (Phone)
+1-302-6745266 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cyberonics, Inc. is a medical device company, engaged in the design, development, sale and marketing of an implantable medical device, the VNS Therapy System, that delivers a therapy, vagus nerve stimulation (VNS) therapy using pulsed electrical signals applied to the vagus nerve for the treatment of refractory epilepsy and treatment-resistant depression (TRD). The Company is also investigating the use of vagus nerve stimulation and other neuromodulation therapy for other indications, including chronic heart failure, and developing non-implantable device solutions for the management of epilepsy. As of April 25, 2014, the Company had 639 employees globally. The applications of VNS Therapy system are into Epilepsy, Depression, and treatment for Chronic Heart Failure.

Officers and directors

Daniel Jeffrey Moore President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Gregory H. Browne Chief Financial Officer, Senior Vice President - Finance
Age: 61
Bio & Compensation  - Reuters
Rohan H. Hoare Ph.D. Chief Operating Officer, Senior Vice President
Age: 49
Bio & Compensation  - Reuters
David S. Wise Senior Vice President, Chief Administrative Officer, Secretary
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Randal L. Simpson Vice President - Operations
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Darren W. Alch Vice President, General Counsel, Assistant Secretary
Age: 48
Bio & Compensation  - Reuters
Mark S. Verratti Vice President - Global Sales
Age: 46
Bio & Compensation  - Reuters
Bruce H. KenKnight Ph.D. Vice President - Emerging Therapy
Age: 53
Bio & Compensation  - Reuters
Bryan D. Olin Ph.D. Vice President - Clinical , Quality & Regulatory
Age: 47
Bio & Compensation  - Reuters
Sherrie L. Perkins Vice President - Marketing & New Business Development
Age: 60
Bio & Compensation  - Reuters